NVIC’s “Ask Nurse Vicky March 10, 2011 NVIC’s “Ask Nurse Vicky” Educates Consumers A new online video health education program produced by the National Vaccine Information Center (NVIC) will feature Vicky Debold, RN, PhD, responding to letters from consumers asking questions about vaccination. Since its founding in 1982, NVIC has responded to letters and telephone […]
GSK makes hefty price cuts for Tykerb and Cervarix in India
scripintelligence 10 March 2011 Anju Ghangurde aghangurde@yahoo.com GlaxoSmithKline has enacted significant price cuts for its breast cancer drug Tykerb (lapatinib) and the cervical cancer vaccine Cervarix in the Indian market, as part of its efforts to broaden access to the products through a flexible pricing approach. GSK told Scrip that the price… Read More
Reportlinker Adds Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017
Reportlinker Adds Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017
NEW YORK, March 9, 2011 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:
Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0312154/Cancer-Vaccines—Pipeline-Assessment-and-Market-Forecasts-to-2017.html
Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist’s new report, “Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global Cancer vaccines market. The report identifies key trends shaping and driving the global Atopic dermatitis disease market. It also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer vaccines sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in house analysis by GlobalData’s team of industry experts.
Determination of Regulatory Review Period for Purposes of Patent Extension; CERVARIX
Federal Register A Notice by the Food and Drug Administration on 03/09/2011 Summary The Food and Drug Administration (FDA) has determined the regulatory review period for CERVARIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of […]
The Difference: Bruesewitz v Berkovitz by F. Edward Yazbak, MD, FAAP
Vaccinationnews The Difference Bruesewitz v Berkovitz 22 years Different Decisions Different US Supreme Courts Different Press and Public Opinions The United States Supreme Court recent decision in Bruesewitz V. Wyeth did not only affect a family. It affected thousands, who after unsuccessfully pursuing a claim through the National Vaccine Injury Compensation Program, will no longer […]
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 40
- Next Page »
